CYBN News

Latest breaking news and updates for CYBN stock.

Track all markets on TradingView

Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare b...

What is the potential upside in market share and revenue if CYB003 receives approval for adjunctive treatment of major depressive disorder? How does CYBIN’s adjunctive MDD therapy prospectus compare to existing standard‑of‑care treatments and to other pipeline candidates in the neuropsychiatry space? Are there any known safety or efficacy signals from earlier Phase 2 data on CYB003 that could influence investor sentiment?
Clinical trials
18 days ago
Read more businesswire

Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental health...

How might the conference influence analyst coverage, target price revisions, or rating changes for CYBN? Are there any potential risks or negative disclosures that could be disclosed during the fireside chat? What is the likelihood of a significant increase in trading volume or volatility around the conference date?
Corporate
19 days ago
Read more businesswire

Taconic and Cyagen Collaborate to Streamline Access to Preclinical Mouse and Rat Models

RENSSELAER, N.Y.--(BUSINESS WIRE)--Taconic Biosciences, a global leader in providing disease specific rodent model solutions and related services, and Cyagen Biosciences, an AI-enabled CRO company ...

Will the partnership drive increased M&A activity in the pre‑clinical animal model space? What impact could this partnership have on the broader biotechnology sector and related investment opportunities? How will the partnership affect the valuation multiples (e.g., P/E, EV/EBITDA) for Cyagen (CYBN) compared to industry peers?
Partnership
21 days ago
Read more businesswire